AstraZeneca PLC (LON:0A4J)

Market Cap	162.76B
Revenue (ttm)	42.56B
Net Income (ttm)	6.02B
Shares Out	n/a
EPS (ttm)	3.85
PE Ratio	27.06
Forward PE	15.81
Dividend	1.20 (1.79%)
Ex-Dividend Date	Feb 21, 2025

Volume	19
Average Volume	8,718
Open	67.00
Previous Close	66.83
Day's Range	67.00 - 67.00
52-Week Range	62.79 - 87.62
Beta	0.18
RSI	44.08
Earnings Date	Jul 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD